Early Imaging Detection of CV Injury after Cancer

描述（由申请人提供）：心血管（CV）损伤导致心肌梗死（MI）、心源性死亡、中风和充血性心力衰竭（CHF）是蒽环类化疗用于辅助治疗乳腺癌、白血病和淋巴瘤的主要障碍。对于需要这种治疗的儿童或成人，没有临床可接受的替代方案。该学术-工业团队将开发和优化一个成本效益高、自动化、可重复的硬件/软件平台，用于获取、分析和报告亚临床和临床CV损伤，识别这种损伤的机制，并预测CV事件风险。这一重要信息可用于临床前治疗

DESCRIPTION (provided by applicant): Cardiovascular (CV) injury leading to myocardial infarction (MI), cardiac death, stroke, and congestive heart failure (CHF) is a major impediment to the curative use of anthracycline-based chemotherapy for the treatment of adjuvant breast cancer, leukemia, and lymphoma. No clinically acceptable alternatives exist for children or adults that require this therapy. The assembled academic-industrial team will develop and optimize a cost-effective, automated, reproducible hardware/software platform that acquires, analyzes, and reports subclinical and clinical CV injury, identifies the mechanisms of this injury and forecasts CV event risks. This important information can be utilized for preclinical treatment protocols that, when administered to other high CV risk populations, reduce the rates of adverse CV events. This well-designed and powered pivotal clinical study to validate these technologies will: " Collect within person longitudinal results before anthracycline exposure and at 3 and 24 months after exposure to determine if short-term results predict long-term subclinical disease that portends an adverse prognosis~ " Determine the efficacy of this new platform in children and adults aged 10 to 80 years~ " Derive population (age, gender, race, and cardiac risk factor-matched) predictive metrics for the platform compared against 6,000 individuals without known coronary artery disease from the existing Multi-Ethnic Study of Atherosclerosis (MESA)~ " Standardize the automated platform to enable medical centers throughout the world with little MRI expertise to reliably and reproducibly perform the studies. This platform innovation is based on strong NCI funded preliminary data and provides a highly significant cost effective solution for a previously unsolved clinical problem that noninvasively defines early CV risk and enables targeted therapeutic interventions to dramatically reduce these risks. Reducing CV events in cancer survivors will reduce overall morbidity in patients with cancer and improve cancer-related survival.